Leonard Girnita

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Docent, Patologi
Forskargruppsledare
Överläkare, Klinisk Patologi

Artiklar

Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2022;107(Suppl_1):S1-S12
It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease
Girnita L; Smith TJ; Janssen JAMJL
Article: ONCOGENE. 2022;41(4):600-611
IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma
Song D; Cismas S; Crudden C; Trocme E; Worrall C; Suleymanova N; Lin T; Zheng H; Seregard S; Girnita A; Girnita L
Article: CANCER RESEARCH. 2021;81(2):501-514
Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth
Crudden C; Shibano T; Song D; Dragomir MP; Cismas S; Serly J; Nedelcu D; Fuentes-Mattei E; Tica A; Calin GA; Girnita A; Girnita L
Article: GASTROENTEROLOGY. 2020;159(6):2146-2162.e33
The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling
Chen B; Dragomir MP; Fabris L; Bayraktar R; Knutsen E; Liu X; Tang C; Li Y; Shimura T; Ivkovic TC; De los Santos MC; Anfossi S; Shimizu M; Shah MY; Ling H; Shen P; Multani AS; Pardini B; Burks JK; Katayama H; Reineke LC; Huo L; Syed M; Song S; Ferracin M; Oki E; Fromm B; Ivan C; Bhuvaneshwar K; Gusev Y; Mimori K; Menter D; Sen S; Matsuyama T; Uetake H; Vasilescu C; Kopetz S; Parker-Thornburg J; Taguchi A; Hanash SM; Girnita L; Slaby O; Goel A; Varani G; Gagea M; Li C; Ajani JA; Calin GA
Article: BRITISH JOURNAL OF OPHTHALMOLOGY. 2020;104(1):26-32
Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm
Fili M; Trocme E; Bergman L; See TRO; Andre H; Bartuma K; Girnita L; All-Eriksson C; Seregard S; Stalhammar G
Article: CANCERS. 2019;11(10):E1579-1579
Prediction of BAP1 Expression in Uveal Melanoma Using Densely-Connected Deep Classification Networks
Sun M; Zhou W; Qi X; Zhang G; Girnita L; Seregard S; Grossniklaus HE; Yao Z; Zhou X; Stalhammar G
Article: GENOME RESEARCH. 2019;29(9):1377-1388
Decrypting noncoding RNA interactions, structures, and functional networks
Fabbri M; Girnita L; Varani G; Calin GA
Article: ONCOTARGET. 2018;9(74):33871-33883
IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line.
Furuta H; Yoshihara H; Fukushima T; Yoneyama Y; Ito A; Worrall C; Girnita A; Girnita L; Yoshida M; Asano T; Komada M; Kataoka N; Chida K; Hakuno F; Takahashi S-I
Article: GENOME RESEARCH. 2018;28(4):432-447
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA &ITCCAT2&IT induce myeloid malignancies via unique SNP-specific RNA mutations
Shah MY; Ferracin M; Pileczki V; Chen B; Redis R; Fabris L; Zhang X; Ivan C; Shimizu M; Rodriguez-Aguayo C; Dragomir M; Van Roosbroeck K; Almeida MI; Ciccone M; Nedelcu D; Cortez MA; Manshouri T; Calin S; Muftuoglu M; Banerjee PP; Badiwi MH; Parker-Thornburg J; Multani A; Welsh JW; Estecio MR; Ling H; Tomuleasa C; Dima D; Yang H; Alvarez H; You MJ; Radovich M; Shpall E; Fabbri M; Rezvani K; Girnita L; Berindan-Neagoe I; Maitra A; Verstovsek S; Fodde R; Bueso-Ramos C; Gagea M; Manero GG; Calin GA
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2018;138(4):882-892
Genome-Wide Screen for MicroRNAs Reveals a Role for miR-203 in Melanoma Metastasis
Lohcharoenkal W; Das Mahapatra K; Pasquali L; Crudden C; Kular L; Ulum YZA; Zhang L; Landen NX; Girnita L; Jagodic M; Stahle M; Sonkoly E; Pivarcsi A
Article: ONCOGENE. 2017;36(41):5734-5744
Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes
Suleymanova N; Crudden C; Shibano T; Worrall C; Oprea I; Tica A; Calin GA; Girnita A; Girnita L
Article: ONCOTARGET. 2017;8(47):82256-82267
Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation
Suleymanova N; Crudden C; Worrall C; Dricu A; Girnita A; Girnita L
Article: ONCOGENE. 2017;36(23):3274-3286
Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma
Worrall C; Suleymanova N; Crudden C; Drakensjo IT; Candrea E; Nedelcu D; Takahashi S-I; Girnita L; Girnita A
Article: CANCER RESEARCH. 2016;76(19):5634-5646
Estrogen Receptor a Promotes Breast Cancer by Reprogramming Choline Metabolism
Jia M; Andreassen T; Jensen L; Bathen TF; Sinha I; Gao H; Zhao C; Haldosen L-A; Cao Y; Girnita L; Moestue SA; Dahlman-Wright K
Article: MOLECULAR THERAPY NUCLEIC ACIDS. 2014;3(7):e172
Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression
Oprea II; Viola JR; Moreno PMD; Simonson OE; Rodin S; Teller N; Tryggvason K; Lundin KE; Girnita L; Smith CIE
Article: PEDIATRIC ENDOCRINOLOGY REVIEWS PER. 2013;10(4):473-484
Novel Mechanisms of Regulation of IGF-1R Action: Functional and Therapeutic Implications
Worrall C; Nedelcu D; Serly J; Suleymanova N; Oprea I; Girnita A; Girnita L
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012;109(50):20620-20625
β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma
Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2012;423(1):122-127
Insulin/insulin-like growth factor (IGF) stimulation abrogates an association between a deubiquitinating enzyme USP7 and insulin receptor substrates (IRSs) followed by proteasomal degradation of IRSs
Yoshihara H; Fukushima T; Hakuno F; Saeki Y; Tanaka K; Ito A; Yoshida M; Iemura S-I; Natsume T; Asano T; Chida K; Girnita L; Takahashi S-I
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012;109(18):7055-7060
Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor
Zheng H; Worrall C; Shen H; Issad T; Seregard S; Girnita A; Girnita L
Article: PLOS ONE. 2011;6(3):e14757
Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP)
Hashemi J; Worrall C; Vasilcanu D; Fryknas M; Sulaiman L; Karimi M; Weng W-H; Lui W-O; Rudduck C; Axelson M; Jernberg-Wiklund H; Girnita L; Larsson O; Larsson C
Article: NEURO-ONCOLOGY. 2010;12(1):19-27
Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma
Yin S; Girnita A; Stromberg T; Khan Z; Andersson S; Zheng H; Ericsson C; Axelson M; Nister M; Larsson O; Ekstrom TJ; Girnita L
Article: ACTA OPHTHALMOLOGICA. 2009;87(4):464-467
Malignant solitary fibrous tumour of the orbit
Girnita L; Sahlin S; Orrego A; Seregard S
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(8):1458-1467
Aberrant intracellular IGF-1R β-subunit makes receptor knockout cells (IGF1R^-/-) susceptible to oncogenic transformation
Natalishvili N; Axelson M; Girnita L; Larsson O; Vasilcanu D
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:35-41
Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:26-34
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: ACTA OPHTHALMOLOGICA. 2008;46:20-25
Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma. Intercorrelation and prognostic implications
Economou MA; Ericsson CA; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:42-49
Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.
Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Article: JOURNAL OF ORGANIC CHEMISTRY. 2008;73(15):5795-5805
New picropodophyllin analogs via palladium-catalyzed allylic alkylation - Hiyama cross-coupling sequences
Vitale M; Prestat G; Lopes D; Madec D; Kammerer C; Poli G; Girnita L
Article: CANCER RESEARCH. 2008;68(14):5669-5677
Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis
Sehat B; Andersson S; Girnita L; Larsson O
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2008;49(6):2620-2626
Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor
Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2008;49(6):2337-2342
Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2008;368(3):793-800
Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth
Toernkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
Article: ONCOGENE. 2008;27(11):1629-1638
Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor:: potential mechanistic involvement of Mdm2 and β-arrestin1
Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
Article: MOLECULAR PHARMACOLOGY. 2008;73(3):930-939
Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin
Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
Article: JOURNAL OF VASCULAR SURGERY. 2007;46(1):108-115
The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling
Razuvaev A; Henderson B; Girnita L; Larsson O; Axelson M; Hedin U; Roy J
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2007;282(15):11329-11338
β-Arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression
Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Vasilcanu D; Girnita A; Lefkowitz RJ; Larsson O
Article: PLOS ONE. 2007;2(4):e340
Role of Ubiquitination in IGF-1 Receptor Signaling and Degradation
Sehat B; Andersson S; Vasilcanu R; Girnita L; Larsson O
Article: BRITISH JOURNAL OF CANCER. 2007;96 Suppl:R2-R6
Role of insulin-like growth factor 1 receptor signalling in cancer.
Larsson O; Girnita A; Girnita L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;347(4):1059-1066
IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-)
Rosengren L; Vasilcanu D; Vasilcanu R; Fickenscher S; Sehat B; Natalishvili N; Naughton S; Yin S; Girnita A; Girnita L; Axelson M; Larsson O
Article: ONCOGENE. 2006;25(22):3186-3195
The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection
Vasilcanu D; Weng W-H; Girnita A; Lui W-O; Vasilcanu R; Axelson M; Larsson O; Larsson C; Girnita L
Article: CLINICAL CANCER RESEARCH. 2006;12(4):1383-1391
The insulin-like growth factor-1 receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells
Girnita A; All-Ericsson C; Economou MA; Åström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: BLOOD. 2006;107(2):669-678
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G₂/M-phase accumulation and apoptosis in multiple myeloma cells
Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Österborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H
Article: BLOOD. 2006;107(2):655-660
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
Menu E; Jernberg-Wiklund H; Stromberg T; De Raeve H; Girnita L; Larsson O; Axelson M; Asosingh K; Nilsson K; Van Camp B; Vanderkerken K
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2005;46(12):4372-4375
Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: Intercorrelation and prognostic implications
Economou MA; All-Ericsson C; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(26):24412-24419
β-arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase
Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Girnita A; Lefkowitz RJ; Larsson O
Article: CLINICAL CANCER RESEARCH. 2005;11(13):4674-4680
Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells:: A novel therapeutic approach
Ulfarsson E; Karström A; Yin SC; Girnita A; Vasilcanu D; Thoren M; Kratz G; Hillman J; Axelson M; Larsson O; Girnita L
Article: CLINICAL CANCER RESEARCH. 2005;11(1):206-216
Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma
Åhlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
Article: ONCOGENE. 2004;23(47):7854-7862
The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway
Vasilcanu D; Girnita A; Girnita L; Vasilcanu R; Axelson M; Larsson O
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2004;45(7):2075-2082
c-Kit-dependent growth of uveal melanoma cells:: A potential therapeutic target?
All-Ericsson C; Girnita L; Müller-Brunotte A; Brodin B; Seregard S; Östman A; Larsson O
Article: CANCER RESEARCH. 2004;64(1):236-242
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
Girnita A; Girnita L; del Prete F; Bartolazzi A; Larsson O; Axelson M
Article: ONCOGENE. 2003;22(48):7628-7631
Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene (Publication with Expression of Concern)
Xie YT; Törnkvist M; Aalto Y; Nilsson G; Girnita L; Nagy B; Knuutila S; Larsson O
Article: MELANOMA RESEARCH. 2003;13(4):325-337
CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage
Gasbarri A; Del Prete F; Girnita L; Martegani MP; Natali PG; Bartolazzi A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2003;100(14):8247-8252
Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor
Girnita L; Girnita A; Larsson O
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2002;43(1):1-8
Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Article: CANCER RESEARCH. 2000;60(18):5278-5283
Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: Functional impact
Girnita L; Girnita A; Brodin B; Xie YT; Nilsson G; Dricu A; Lundeberg J; Wejde J; Bartolazzi A; Wiman KG; Larsson O
Article: ONCOGENE. 2000;19(37):4298-4301
A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells
Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Article: MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2000;165(1-2):131-137
Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway
Kanter-Lewensohn L; Girnita L; Girnita A; Dricu A; Olsson G; Leech L; Nilsson G; Hilding A; Wejde J; Brismar K; Larsson O
Article: ONCOLOGY RESEARCH. 2000;15(1):67-72
Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications
Girnita L; Wang M; Xie YT; Nilsson G; Dricu A; Wejde J; Larsson O
Article: GROWTH FACTORS. 2000;17(3):193-202
Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27^Kip1 in melanocytic tumors:: A potential regulatory role of IGF-1 pathway in distribution of p27^Kip1 between different cyclins
Kanter-Lewensohn L; Dricu A; Girnita L; Wejde J; Larsson O
Article: EXPERIMENTAL CELL RESEARCH. 1999;246(1):38-46
Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells
Wang M; Xie YT; Girnita L; Nilsson G; Dricu A; Wejde J; Larsson O
Article: ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY. 1998;44(1-4):65-71
The coexistence of atypical intraductal hyperplasias with breast carcinoma.
Bogdan F; Gîrniţă L; Florescu M; Simionescu C; Crăiţoiu S; Comănescu V
Visa fler

Alla övriga publikationer

Corrigendum: ONCOGENE. 2023;42(11):858
IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma (vol 41, pg 600, 2022)
Song D; Cismas S; Crudden C; Trocme E; Worrall C; Suleymanova N; Lin T; Zheng H; Seregard S; Girnita A; Girnita L
Corrigendum: ONCOGENE. 2023;42(5):407-408
Correction: The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway.
Vasilcanu D; Girnita A; Girnita L; Vasilcanu R; Axelson M; Larsson O
Corrigendum: ONCOGENE. 2023;42(3):253
Correction: Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1.
Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
Editorial comment: FRONTIERS IN ENDOCRINOLOGY. 2023;14:1138326
Editorial: DNA damage response pathways meet endocrine systems
Werner H; Girnita L
Editorial comment: SCIENCE SIGNALING. 2020;13(633):eabb7887
The tale of a tail: The secret behind IGF-1R's oncogenic power
Crudden C; Girnita L
Review: CELLS. 2019;8(12):E1638-1638
Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer
Chen B; Li J; Chi D; Sahnoune I; Calin S; Girnita L; Calin GA
Review: CELLS. 2019;8(10):E1223-1223
Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey
Crudden C; Song D; Cismas S; Trocme E; Pasca S; Calin GA; Girnita A; Girnita L
Review: CHROMATIN AND GENOMIC INSTABILITY IN CANCER. 2018;339:1-40
Blurring Boundaries: Receptor Tyrosine Kinases as functional G Protein-Coupled Receptors
Crudden C; Shibano T; Song D; Suleymanova N; Girnita A; Girnita L
Review: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2017;55(5):705-714
Non-coding RNAs: the cancer genome dark matter that matters!
Ling H; Girnita L; Buda O; Calin GA
Review: ADVANCES IN AGGREGATION INDUCED EMISSION MATERIALS IN BIOSENSING AND IMAGING FOR BIOMEDICAL APPLICATIONS, PT A. 2016;141:277-311
When Phosphorylation Encounters Ubiquitination: A Balanced Perspective on IGF-1R Signaling
Girnita L; Takahashi S-I; Crudden C; Fukushima T; Worrall C; Furuta H; Yoshihara H; Hakuno F; Girnita A
Review: GROWTH HORMONE & IGF RESEARCH. 2015;25(1):2-12
The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?
Crudden C; Ilic M; Suleyrnanova N; Worrall C; Girnita A; Girnita L
Review: FRONTIERS IN ENDOCRINOLOGY. 2015;6:64
Targeting the IGF-1R: the tale of the tortoise and the hare
Crudden C; Girnita A; Girnita L
Review: CELLULAR AND MOLECULAR LIFE SCIENCES. 2014;71(13):2403-2427
Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation
Girnita L; Worrall C; Takahashi S-I; Seregard S; Girnita A
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2009;7(3):16
β-arrestin-dependent signaling by IGF-1R regulates the Ras induced transformation of mammalian cells
Zheng H; Natalishvili N; Mateoiu C; Girnita A; Girnita L
Review: BRITISH JOURNAL OF CANCER. 2005;92(12):2097-2101
Role of insulin-like growth factor 1 receptor signalling in cancer
Larsson O; Girnita A; Girnita L
Meeting abstract: BLOOD. 2004;104(11):184A-185A
Targeting the insulin-like growth factor-i receptor (IGF-IR) in multiple myeloma cells using selective IGF-IR tyrosine kinase inhibitors.
Stromberg T; Ekman S; Girnita L; Lennartsson J; Hellman U; Carlson K; Osterborg A; Vanderkerken K; Axelson M; Larsson O; Jernberg-Wiklund H
Meeting abstract: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2004;50(3):P117
Possible use of flavonoids as cell growth inhibitors in malignant melanoma
Girnita A; Girnita L; Axelson M; Larsson O
Doctoral thesis: 2002
Growth factor pathways in human cancer : functional and therapeutic implications
Girnita L

Anställningar

Annan Grund, Onkologi-Patologi, Karolinska Institutet, 2025-2025
Senior Forskare, Onkologi-Patologi, Karolinska Institutet, 2022-2025

Examina och utbildning

Docent, Patologi, Karolinska Institutet, 2008
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2002

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI